Urologische Klinik und Poliklinik
Refine
Has Fulltext
- yes (75)
Is part of the Bibliography
- yes (75)
Year of publication
Document Type
- Journal article (47)
- Doctoral Thesis (28)
Keywords
- prostate cancer (18)
- PSMA (6)
- Prostatakrebs (6)
- radioligand therapy (6)
- Prostatakarzinom (5)
- Nierenzellkarzinom (4)
- PET/CT (4)
- PSA (4)
- angiogenesis (4)
- biomarker (4)
Institute
- Urologische Klinik und Poliklinik (75)
- Klinik und Poliklinik für Nuklearmedizin (12)
- Comprehensive Cancer Center Mainfranken (11)
- Pathologisches Institut (8)
- Theodor-Boveri-Institut für Biowissenschaften (8)
- Medizinische Klinik und Poliklinik II (5)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (4)
- Medizinische Klinik und Poliklinik I (4)
- Center for Computational and Theoretical Biology (3)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
Sonstige beteiligte Institutionen
The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa.